Lundbeck silent on shutdown of Indian operations

Despite a complete withdrawal from the market of one of the world's most populous nations, the Danish pharmaceutical giant doesn't want to comment on the reason why, or whether any other domestic operations are facing closedowns.

Lundbeck's interest in the Indian market has suffered a blow, but the company doesn't want to say why it is suddenly ceasing operations completely. | Photo: Foto af Ulrich Quistgaard

With over 1.3 billion people, India should, on the face of it, appear an attractive drug market for life science firms. Nonetheless, Lundbeck has decided to cease its operations in the Central Asian country completely.

The company doesn't want to reveal what precisely led to this development.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs